Literature DB >> 7676642

Delayed onset postvaccinal mucosal disease as a result of genetic recombination between genotype 1 and genotype 2 BVDV.

J F Ridpath1, S R Bolin.   

Abstract

Bovine viral diarrhea viruses (BVDV) are segregated into two genotypes, BVDV 1 and BVDV 2. Viruses within both genotypes may exist as one of two biotypes, cytopathic or noncytopathic. A highly fatal form of BVDV termed mucosal disease (MD) occurs when an animal persistently infected with noncytopathic BVDV becomes superinfected with cytopathic BVDV. In this study, we characterized a noncytopathic (BVDV2-125nc)/cytopathic (BVDV2-125c) viral pair isolated from an animal that died of MD 3 months after vaccination with modified-live BVDV1-NADL. In comparison to BVDV2-125nc, BVDV2-125c contained a 366-nucleotide insertion. The insertion was in the correct reading frame for the large open reading frame of the BVDV genome and occurred in the portion of the genome that codes for the p125 viral polypeptide. There was a 99% identity between the inserted sequences found in BVDV2-125c and sequences from the vaccine virus BVDV1-NADL. These data suggest that MD was induced after a recombination between noncytopathic BVD2-125nc and cytopathic vaccine virus BVDV1-NADL created the cytopathic virus BVDV2-125c.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7676642     DOI: 10.1006/viro.1995.1480

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  10 in total

1.  A monoclonal antibody-based immunoperoxidase monolayer (micro-isolation) assay for detection of type 1 and type 2 bovine viral diarrhea viruses.

Authors:  D Deregt; S Prins
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

2.  RNA recombination between persisting pestivirus and a vaccine strain: generation of cytopathogenic virus and induction of lethal disease.

Authors:  P Becher; M Orlich; H J Thiel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Cytopathogenicity of a pestivirus correlates with a 27-nucleotide insertion.

Authors:  N Tautz; G Meyers; R Stark; E J Dubovi; H J Thiel
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Detection and characterization of genetic recombination in cytopathic type 2 bovine viral diarrhea viruses.

Authors:  J F Ridpath; J D Neill
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Authentic and chimeric full-length genomic cDNA clones of bovine viral diarrhea virus that yield infectious transcripts.

Authors:  V B Vassilev; M S Collett; R O Donis
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

6.  Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus.

Authors:  Charles E McGee; Konstantin A Tsetsarkin; Bruno Guy; Jean Lang; Kenneth Plante; Dana L Vanlandingham; Stephen Higgs
Journal:  PLoS One       Date:  2011-08-03       Impact factor: 3.240

Review 7.  Variability and Global Distribution of Subgenotypes of Bovine Viral Diarrhea Virus.

Authors:  Kadir Yeşilbağ; Gizem Alpay; Paul Becher
Journal:  Viruses       Date:  2017-05-26       Impact factor: 5.048

8.  BVD-2 outbreak leads to high losses in cattle farms in Western Germany.

Authors:  Jörn Gethmann; Timo Homeier; Mark Holsteg; Horst Schirrmeier; Michael Saßerath; Bernd Hoffmann; Martin Beer; Franz J Conraths
Journal:  Heliyon       Date:  2015-09-21

9.  Response of calves persistently infected with noncytopathic bovine viral diarrhea virus (BVDV) subtype 1b after vaccination with heterologous BVDV strains in modified live virus vaccines and Mannheimia haemolytica bacterin-toxoid.

Authors:  Robert W Fulton; Douglas L Step; Julia F Ridpath; Jeremiah T Saliki; Anthony W Confer; Bill J Johnson; Robert E Briggs; R V Hawley; Lurinda J Burge; Mark E Payton
Journal:  Vaccine       Date:  2003-06-20       Impact factor: 3.641

Review 10.  Origination and consequences of bovine viral diarrhea virus diversity.

Authors:  Steven R Bolin; Daniel L Grooms
Journal:  Vet Clin North Am Food Anim Pract       Date:  2004-03       Impact factor: 3.357

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.